Main Content start here
Main Layout
Report Description

Report Description

Global asthma treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of asthma, growing R&D activities and increasing investment in healthcare infrastructure. Asthma is one of the major public health problem in many countries, particularly in the United States. The high burden of the disease has created a strong demand for effective Asthma Treatment. This has led to significant investment in the development of medications that can prevent Asthma Infection or reduce its severity. The World Health Organization (WHO) estimates that asthma affects around 235 million people worldwide and is responsible for approximately 383,000 deaths annually.

 

Biologic medications, also known as immunomodulators, are a new class of drugs that target specific molecules involved in the immune response. Examples of biologic medications used for asthma include omalizumab, mepolizumab, and benralizumab. These medications reduce the frequency and severity of asthma exacerbations in patients with severe, uncontrolled asthma. There is growing interest in the use of digital health technologies, such as mobile apps and wearable devices, for the management of asthma. These tools may help patients to monitor their symptoms, track their medication use, and receive personalized treatment recommendations.


Governments and private agencies often run public awareness campaigns to educate people about the causes, symptoms, and treatment of asthma. These campaigns include social media campaigns, television and radio ads, and educational materials such as brochures and pamphlets. This increases awareness among people and results in the growth of global asthma treatment market.

 

Private agencies may engage in advocacy and lobbying efforts to promote policies and initiatives that support asthma treatment and management. This can include efforts to improve insurance coverage for asthma medications, increase funding for asthma research, and promote clean air initiatives to reduce asthma triggers. As the private agencies make people aware this increases the global asthma market.

 

Increasing Prevalence of Asthma


The growing prevalence of asthma is one of the key drivers of the global asthma treatment market. Asthma is a chronic respiratory condition that is caused by a combination of genetic and environmental factors, which is transmitted to humans through genetics, environmental factors, respiratory infection, obesity, and stress. Global Asthma Report 2018 predicts that asthma will continue to be a significant global health concern, with an increasing burden in low- and middle-income countries. The report notes that without significant improvements in prevention, diagnosis, and treatment, the number of asthma-related deaths may increase by 20% by 2030. The growing prevalence of asthma has led to increased public awareness of the condition. This has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management. According to Global Asthma Report 2018, an estimated 339 million people worldwide were affected by asthma in 2016.

 

As the prevalence of asthma increases, there is a greater need for healthcare infrastructure to support the diagnosis and treatment of the condition. This can lead to increased investment in healthcare systems, including the development of new clinics, hospitals, and other healthcare facilities. The World Health Organization (WHO) reports that there has been an increase in public awareness about asthma globally in recent years, which has helped to reduce stigma around the condition and promote better understanding of the need for effective treatment and management.

The growing prevalence of asthma drives research and development in the field of asthma treatment. As more people are diagnosed with asthma, there is a greater need for new and more effective treatments to manage the condition.

 

Providing Access to Healthcare


Providing access to healthcare is essential for promoting the global asthma treatment market. Asthma is a chronic condition that requires ongoing management and treatment, including regular monitoring, medication, and follow-up care. People with asthma who do not have access to healthcare may not receive appropriate treatment, which can lead to serious complications, such as hospitalization, emergency room visits, and even death. According to the Global Asthma Report 2018, asthma is estimated to have caused 461,000 deaths globally in 2016.

 

Access to healthcare can promote the global asthma treatment market in several ways. Firstly, it can help to identify people with asthma early, allowing for prompt diagnosis and treatment. This can prevent the development of more severe asthma symptoms and reduce the need for emergency care. Additionally, healthcare providers can provide education and support people with asthma, helping them to understand their condition and manage their symptoms effectively. In the United States, it is estimated that around 25 million people have asthma, and many of these are diagnosed in childhood due to access to healthcare and regular monitoring of respiratory health.

 

Access to healthcare can ensure that people with asthma have access to appropriate medications and treatment options. This can include both short-term medications to manage symptoms as well as long-term medications to prevent asthma attacks from occurring. Access to healthcare can provide people with asthma with the access to specialists, such as allergists or pulmonologists, who can provide more specialized care and treatment. anticipated in the growth of global asthma treatment market.

 

Increasing Investment in Research and Development

 

Pharmaceutical companies are investing heavily in research and development to develop new and innovative asthma treatments. Asthma is a complex disease that requires ongoing management and treatment, and there is a need for new and improved treatments to address unmet medical needs. The National Institutes of Health (NIH) in the United States provides over USD 100 million in funding for asthma research each year, supporting research into new treatments, disease mechanisms, and prevention strategies. It can help to identify new drug targets and treatment options for asthma. This can include the development of novel drugs, biologics, or combination therapies that may provide more effective and targeted treatment options for people with asthma.

 

Investment in R&D can help to improve the understanding of the underlying mechanisms of asthma and identify new biomarkers for diagnosis and monitoring. This can enable more personalized treatment approaches, which may lead to better outcomes and reduced healthcare costs. Investment in R&D can help to improve asthma management and education, leading to better self-management of the disease and reduced healthcare utilization. It can include the development of new devices and technologies for monitoring and managing asthma symptoms, as well as education programs for healthcare providers and patients.

 



Download Free Sample Report 


Recent Developments


In September 2021, AstraZeneca announced the FDA approval of its new biologic therapy Fasenra (benralizumab) for the treatment of eosinophilic asthma in patients aged six years and older.

In May 2020, Sanofi and Regeneron Pharmaceuticals announced positive results from a Phase 3 trial of their biologic therapy Dupixent (dupilumab) for the treatment of moderate-to-severe asthma.

In January 2020, Novartis announced the FDA approval of its asthma drug Xolair (omalizumab) for the treatment of nasal polyps in adult patients.

 

Market Segmentation


Global asthma treatment market can be segmented by drug class, mode of administration, distribution channel, and region. Based on drug class, global asthma treatment market can be divided into short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), inhaled corticosteroids (ICS), leukotriene modifiers, immunomodulators, combination drugs, and others. Based on mode of administration, the global asthma treatment market is divided into inhalers, nebulizers, and oral medications. Based on distribution channel, the global asthma treatment market is divided into hospital pharmacies, retail pharmacies, online pharmacies, and others. Regionally, the global asthma treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

 

Market Players

GlaxoSmithKline, Plc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Gmbh, Merck & Co. Inc, Novartis AG, Sanofi SA, Roche Holding AG, Regeneron Pharmaceutical Inc, Pfizer Inc. are some of the leading players operating in the global asthma treatment market.

 

Attribute

Details

Base Year

2022

Historic Data

2018 – 2021

Estimated Year

2023

Forecast Period

2024 – 2028

Quantitative Units

Revenue in USD Million, and CAGR for 2018-2023 and 2024-2028

Report coverage

Revenue forecast, volume forecast, company share, competitive landscape, growth factors, and trends

Segments covered

Drug Class

Mode of Administration

Distribution Channel

Regional Scope

North America, Europe, Asia Pacific, South America, Middle East & Africa

Country Scope

United States, Canada, Mexico, United Kingdom, Germany, France, Italy, Spain, India, Japan, South Korea, Australia, Vietnam, Indonesia, Myanmar, Brazil, Colombia, South Africa, Saudi Arabia, UAE

Key companies profiled

GlaxoSmithKline, Plc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Gmbh, Merck & Co Inc., Novartis AG, Sanofi SA, Roche Holding AG, Regeneron Pharmaceutical Inc, Pfizer Inc.

Customization scope

10% free report customization with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Delivery Format

PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

 

Report Scope:

In this report, global asthma treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Asthma Treatment Market, By Drug Type:

o      Short Acting Beta-Agonists (SABA)

o      Long-Acting Beta-Agonists (LABA)

o      Inhaled Corticosteroids (ICS)

o      Leukotriene Modifiers

o      Immunomodulator

o      Combination Drugs

o      Others

  • Asthma Treatment Market, By Mode of Administration:

o      Inhalers

o      Nebulizers

o      Oral Medications

  • Asthma treatment Market, By Distribution Channel

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

o   Others

  • Asthma Treatment Market, By Region:

o      North America

o   United States

o   Canada

o   Mexico

o      Europe

o   Germany

o   United Kingdom

o   France

o   Italy

o   Spain

o      Asia Pacific

o   India

o   Japan

o   South Korea

o   Australia

o   China

o      South America

o   Brazil

o   Colombia

o      Middle East & Africa

o   South Africa

o   Saudi Arabia

o   UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global asthma treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Global Asthma Treatment Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]
Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.    Markets Covered

1.2.2.    Years Considered for Study

1.2.3.    Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validations

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Asthma Treatment Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Drug Class (Short acting beta-agonists (SABA), Long-acting beta-agonists (LABA), Inhaled corticosteroids (ICS), Leukotriene modifiers, Immunomodulators, Combination drugs, Others)

5.2.2.    By Mode Of Administration (Inhalers, Nebulizers, Oral medications)

5.2.3.    By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies, Others)

5.2.4.    By Region

5.2.5.    By Company (2022)

5.3.  Product Map

5.3.1.    By Drug Class

5.3.2.    By Mode of Administration

5.3.3.    By Distribution Channel

6.    North America Asthma Treatment Market Outlook

6.1.  Market Size & Forecast       

6.1.1.    By Value

6.2.  Market Share & Forecast

6.2.1.    By Drug Class

6.2.2.    By Mode of Administration

6.2.3.    By Distribution Channel

6.2.4.    By Country

6.3.  North America: Country Analysis

6.3.1.    United States Asthma Treatment Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Drug Class

6.3.1.2.2.           By Mode of Administration

6.3.1.2.3.           Distribution Channel

6.3.2.    Canada Asthma Treatment Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Drug Class

6.3.2.2.2.           By Mode of Administration

6.3.2.2.3.           By Distribution Channel

6.3.3.    Mexico Asthma Treatment Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Drug Class

6.3.3.2.2.           By Mode of Administration

6.3.3.2.3.           By Distribution Channel

7.    Europe Asthma Treatment Market Outlook

7.1.  Market Size & Forecast       

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Drug Class

7.2.2.    By Mode of Administration

7.2.3.    By Distribution Channel

7.2.4.    By Country

7.3.  Europe: Country Analysis

7.3.1.    France Asthma Treatment Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Drug Class

7.3.1.2.2.           By Mode of Administration

7.3.1.2.3.           By Distribution Channel

7.3.2.    Germany Asthma Treatment Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Drug Class

7.3.2.2.2.           By Mode of Administration

7.3.2.2.3.           By Distribution Channel

7.3.3.    United Kingdom Asthma Treatment Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Drug Class

7.3.3.2.2.           By Mode of Administration

7.3.3.2.3.           By Distribution Channel

7.3.4.    Italy Asthma Treatment Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Drug Class

7.3.4.2.2.           By Mode of Administration

7.3.4.2.3.           By Distribution Channel

7.3.5.    Spain Asthma Treatment Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Drug Class

7.3.5.2.2.           By Mode of Administration

7.3.5.2.3.           By Distribution Channel

8.    Asia-Pacific Asthma Treatment Market Outlook

8.1.  Market Size & Forecast       

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Drug Class

8.2.2.    By Mode of Administration

8.2.3.    By Distribution Channel

8.2.4.    By Country

8.3.  Asia-Pacific: Country Analysis

8.3.1.    India Asthma Treatment Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Drug Class

8.3.1.2.2.           By Mode of Administration

8.3.1.2.3.           By Distribution Channel

8.3.2.    Japan Asthma Treatment Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Drug Class

8.3.2.2.2.           By Mode of Administration

8.3.2.2.3.           By distribution Channel

8.3.3.    South Korea Asthma Treatment Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Drug Class

8.3.3.2.2.           By Mode of Administration

8.3.3.2.3.           By Distribution Channel

8.3.4.    Australia Asthma Treatment Market Outlook

8.3.4.1.        Market Size & Forecast

8.3.4.1.1.           By Value

8.3.4.2.        Market Share & Forecast

8.3.4.2.1.           By Drug Class

8.3.4.2.2.           By Mode of Administration

8.3.4.2.3.           By Distribution Channel

9.    South America Asthma Treatment Market Outlook

9.1.  Market Size & Forecast       

9.1.1.    By Value

9.2.  Market Share & Forecast

9.2.1.    By Drug Class

9.2.2.    By Mode of Administration

9.2.3.    By Distribution Channel

9.2.4.    By Country

9.3.  South America: Country Analysis

9.3.1.    Brazil Asthma Treatment Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Drug Class

9.3.1.2.2.           By Mode of Administration

9.3.1.2.3.           By Distribution Channel

9.3.2.    Argentina Asthma Treatment Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Drug Class

9.3.2.2.2.           By Mode of Administration

9.3.2.2.3.           By Distribution Channel

9.3.3.    Colombia Asthma Treatment Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Drug Class

9.3.3.2.2.           By Mode of Administration

9.3.3.2.3.           By Distribution Channel

10. Middle East and Africa Asthma Treatment Market Outlook

10.1.             Market Size & Forecast        

10.1.1. By Value

10.2.             Market Share & Forecast

10.2.1. By Drug Class

10.2.2. By Mode of Administration

10.2.3. By Distribution Channel

10.2.4. By Country

10.3.             MEA: Country Analysis

10.3.1. South Africa Asthma Treatment Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Drug Class

10.3.1.2.2.         By Mode of Administration

10.3.1.2.3.         By Distribution Channel

10.3.2. Saudi Arabia Asthma Treatment Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Drug Class

10.3.2.2.2.         By Mode of Administration

10.3.2.2.3.         By Distribution Channel

10.3.3. UAE Asthma Treatment Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Drug Class

10.3.3.2.2.         By Mode of Administration

10.3.3.2.3.         By Distribution Channel

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Development

12.2.             Mergers & Acquisitions

12.3.             Product Launches

13. Global Asthma Treatment Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Products

15. Competitive Landscape

15.1.             Business Overview

15.2.             Product Offerings

15.3.             Recent Developments

15.4.             Key Personnel

15.5.             SWOT Analysis

15.5.1. GlaxoSmithKline, Plc.

15.5.2. AstraZeneca Plc

15.5.3. Teva Pharmaceutical Industries Ltd

15.5.4. Boehringer Ingelheim Gmbh

15.5.5. Merck & Co. Inc

15.5.6. Novartis AG

15.5.7. Sanofi SA

15.5.8. Roche Holding AG

15.5.9. Regeneron Pharmaceutical Inc

15.5.10.              Pfizer Inc.

16. Strategic Recommendations

Figures and Tables

Frequently asked questions

Frequently asked questions

Factors driving growth in the global asthma treatment market include increasing prevalence of asthma coupled with increasing awareness related to early disease diagnosis and treatment.

Some of the key players in the global asthma treatment market include companies such as GlaxoSmithKline, Plc., AstraZeneca Plc, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim Gmbh, Merck & Co Inc., Novartis AG, Sanofi SA, Roche Holding AG, Regeneron Pharmaceutical Inc, Pfizer Inc.

The inhaled corticosteroids (ICS) segment is expected to dominate the global asthma treatment market due to high efficiency of ICS in reducing airway inflammation.

The primary challenge that the global asthma treatment market will have to overcome in the upcoming years is the high cost of medication and lack of proper diagnostics.

Related Reports